← boardnext 2026-10
TENX
Tenax Therapeutics, Inc.distress 2/10 · well-funded / low risk$14.70-1%today-20% from 52w high
Lead: PH-HFpEF
Revenue
pre-revenue
Liquidity
$119M
Runway
3.1 yrs
Shares 1y
+481%
Price & events
-0.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-2.5%
1W
+7.8%
1M
+5.2%
3M
+0.0%
6M
+142.8%
1Y
+344.1%
2Y
-99.5%
5Y
-99.5%
All
Overview
- Market Cap
- $389.92M
- Volume
- 80.65K
- 52 Week Range
- $5.80 – $18.32
- Total Shares
- 26.53M
- Float Shares
- 26.47M
- Short %
- 6.82%
- % Held by Insiders
- 0.12%
- % Held by Institutions
- 76.42%
- RVOL
- 0.06x
- Beta
- 0.91
Pipeline stages · 1 programs
TNX-103
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10 Estimated 50% readout ~2026-12-15 | Phase 3 | TNX-103 | Pulmonary Hypertension | — | recruiting |
| 2028-06-30 Estimated 50% readout ~2028-09-13 | Phase 3 | TNX-103 | Pulmonary Hypertension Associated With HFpEF | — | recruiting |
| 2029-03 Estimated 50% readout ~2029-05-15 | Phase 3 | TNX-103 | Pulmonary Hypertension Associated With HFpEF | — | enrolling by invitation |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 6
- end of 2027Guided 40%enrollment completesecondaryPhase 3TNX-103 · LEVEL-2 enrollment completion expected by end of 2027SEC 8-K
- second half of 2026Guided 55%readoutPhase 3TNX-103 · LEVEL topline data expected in second half of 2026SEC 8-K
- August 2026Estimated 45%readoutPhase 3TNX-103 · Topline data from Phase 3 LEVEL trialSEC 8-K
- first half of 2026enrollment completesecondaryPhase 3TNX-103 · LEVEL enrollment completion expected in first half of 2026SEC 8-K
- 2025trial initiationsecondaryPhase 3Oral levosimendan (TNX-103) · Initiate second Phase 3 study for PH-HFpEFSEC 8-K
- 2025trial initiationsecondaryPhase 3TNX-103 · Initiate second registrational Phase 3 study LEVEL-2SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $35 (+136% upside) · 8 analysts
- 2026-07-02Chardan CapitalBuy
- 2026-06-24Cantor FitzgeraldOverweight
- 2026-06-22GuggenheimBuy
- 2026-06-22Chardan CapitalBuy
- 2026-06-12Piper SandlerOverweight
- 2026-03-17Cantor FitzgeraldOverweight
Competitors — PH-HFpEF
- TECXTectonic Therapeutic, Inc.$589M · D0
Recent news
- 2026-07-22TENX Initiates Coverage On Evercore ISI Group -- Rating Set to O - GuruFocus
- 2026-07-22Evercore ISI initiates Tenax Therapeutics stock coverage with outperform rating - Investing.com
- 2026-07-22Evercore ISI initiates Tenax Therapeutics stock coverage with outperform rating - Investing.com
- 2026-07-21Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know - Yahoo Finance
- 2026-07-19Tenax Therapeutics (TENX) Rises 5.11% as Buying Pressure Intensifies - Volume Rate Change - dars.gov.et
- 2026-07-18Tenax Therapeutics Inc. (TENX) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Sentiment - dars.gov.et
- 2026-07-18Total assets of Tenax Therapeutics, Inc. – DUS:YBO0 - TradingView
- 2026-07-17Tenax Therapeutics (TENX) gets updated 3.3% ownership filing from Millennium group - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.